Guardant Health Business Segments — Revenue increased by 7.3% to $301.67M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.3%, from $203.47M to $301.67M. Over 3 years (FY 2022 to FY 2025), Business Segments — Revenue shows an upward trend with a 29.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market demand and successful commercial execution, while a decrease may signal market saturation or competitive pressure.
This represents the total gross income generated by the company's primary business segment through the sale of diagnosti...
Standard revenue reporting across life sciences and diagnostics peers.
gh_segment_reportable_segment_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $112.38M | $112.38M | $112.38M | $112.38M | $140.99M | $140.99M | $140.99M | $140.99M | $168.49M | $177.24M | $191.48M | $201.81M | $203.47M | $232.09M | $265.20M | $281.27M | $301.67M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +25.5% | +0.0% | +0.0% | +0.0% | +19.5% | +5.2% | +8.0% | +5.4% | +0.8% | +14.1% | +14.3% | +6.1% | +7.3% |
| YoY Change | — | — | — | — | +25.5% | +25.5% | +25.5% | +25.5% | +19.5% | +25.7% | +35.8% | +43.1% | +20.8% | +30.9% | +38.5% | +39.4% | +48.3% |